Want to see HK:2096 full AI Analyst Report?
Top Page
Simcere Pharmaceutical Group Limited
(2096)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$11.00
▼(-5.17% Downside)
Action:Upgraded
Date:10/03/26
Overall score is driven primarily by strong financial performance—high profitability, improved 2025 growth, and a low-leverage balance sheet—partly offset by historically inconsistent free cash flow. Technical indicators are mixed with slightly negative momentum versus key moving averages, while valuation is reasonable with a mid-range P/E and modest dividend yield.
Positive Factors
Revenue Re-acceleration
Revenue expansion resumed meaningfully in 2025 after a nearly flat 2024, indicating renewed commercial momentum across the pharmaceutical portfolio. If maintained, this growth can broaden the earnings base, support reinvestment in specialty medicines, and strengthen the company’s position in China’s healthcare channels.
Negative Factors
Uneven Cash Conversion
Although recent cash generation improved, negative free cash flow in multiple prior years and only partial conversion of 2025 earnings into free cash flow indicate uneven earnings quality. This may constrain the consistency of internally funded investment, distributions, and debt servicing over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Re-acceleration
Revenue expansion resumed meaningfully in 2025 after a nearly flat 2024, indicating renewed commercial momentum across the pharmaceutical portfolio. If maintained, this growth can broaden the earnings base, support reinvestment in specialty medicines, and strengthen the company’s position in China’s healthcare channels.
Read all positive factors
Simcere Pharmaceutical Group Limited (2096) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$26.04B
Dividend Yield2.04%
Average Volume (3M)4.06M
Price to Earnings (P/E)14.1
Beta (1Y)0.63
Revenue Growth27.24%
EPS Growth79.48%
CountryHK
Employees7,064
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,568,198,700
10 Day Avg. Volume4,876,410
30 Day Avg. Volume4,062,607
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.84
Price to Sales (P/S)3.46
P/FCF Ratio23.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.77Price Target Upside61.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Simcere Pharmaceutical Group Limited Business Overview & Revenue Model
Company Description
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including dis...
How the Company Makes Money
Simcere primarily makes money by selling pharmaceutical products. Its core revenue stream is product sales generated from (1) innovative/specialty drugs that the company develops and commercializes and (2) branded generic medicines and other estab...
Simcere Pharmaceutical Group Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.66B | 7.73B | 6.64B | 6.61B | 6.32B | 5.00B |
| Gross Profit | 7.18B | 6.31B | 5.32B | 4.98B | 5.00B | 3.92B |
| EBITDA | 2.06B | 1.80B | 1.47B | 1.08B | 889.99M | 485.14M |
| Net Income | 1.56B | 1.34B | 733.16M | 714.76M | 930.87M | 1.51B |
Balance Sheet | ||||||
| Total Assets | 15.46B | 14.73B | 11.51B | 10.85B | 10.78B | 10.16B |
| Cash, Cash Equivalents and Short-Term Investments | 4.06B | 3.62B | 1.94B | 2.02B | 2.62B | 2.18B |
| Total Debt | 2.44B | 1.20B | 1.21B | 1.43B | 1.51B | 1.64B |
| Total Liabilities | 5.81B | 5.31B | 4.44B | 3.63B | 3.64B | 3.70B |
| Stockholders Equity | 9.42B | 9.41B | 7.07B | 7.22B | 7.13B | 6.44B |
Cash Flow | ||||||
| Free Cash Flow | 2.19B | 1.15B | 628.54M | -828.81M | 676.71M | -411.46M |
| Operating Cash Flow | 2.79B | 2.01B | 1.39B | 151.05M | 1.35B | -201.97M |
| Investing Cash Flow | -2.95B | -1.33B | -1.05B | 1.09B | 68.31M | -435.50M |
| Financing Cash Flow | 621.99M | 894.39M | -407.40M | -894.83M | -753.68M | -1.62B |
Simcere Pharmaceutical Group Limited Technical Analysis
Negative
11.60
Price Trends
11.22
Negative
11.37
Negative
11.50
Negative
Market Momentum
-0.30
Positive
35.24
Neutral
17.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2096, the sentiment is Negative. The current price of 11.6 is above the 20-day moving average (MA) of 10.82, above the 50-day MA of 11.22, and above the 200-day MA of 11.50, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 35.24 is Neutral, neither overbought nor oversold. The STOCH value of 17.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2096.
Simcere Pharmaceutical Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$26.04B | 14.11 | 16.54% | 2.04% | 27.24% | 79.48% | |
65 Neutral | HK$16.81B | 12.42 | 17.47% | ― | 146.27% | ― | |
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
52 Neutral | HK$21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% | |
41 Neutral | HK$7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
* Healthcare Sector Average
HK:2096
Simcere Pharmaceutical Group Limited
10.14
-2.85
-21.96%
HK:9688
Zai Lab Ltd
17.37
-3.65
-17.36%
HK:9969
InnoCare Pharma Ltd.
11.25
-3.37
-23.05%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.44
-42.85%
HK:2616
CStone Pharmaceuticals
4.94
-1.28
-20.58%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.04
-29.00%
Simcere Pharmaceutical Group Limited Corporate Events
Simcere Wins China Approval for RSV Antibody Yingmule, Strengthening Pediatric Infectious Disease Portfolio
Sep 3, 2026
Simcere Pharmaceutical Group Limited has secured approval from China’s National Medical Products Administration to market Yingmule, a domestic Class 1 innovative biologic, for preventing respiratory syncytial virus lower respiratory tract in...
Simcere Out-licenses Tri-specific Antibody SIM0660 to Roche in Major Global Deal
Sep 1, 2026
Simcere Pharmaceutical Group Limited, an RD-focused pharma player in neuroscience, oncology, autoimmune and anti-infection therapies, is building a portfolio around high-need disease areas. Through internal innovation and collaborations with globa...
Simcere Grants 795,000 RSUs to Employees Under 2021 Incentive Scheme
Aug 21, 2026
Simcere Pharmaceutical Group has granted 795,000 restricted share units at nil consideration to eight employee participants under its 2021 RSU Scheme, with the awards funded by previously lapsed shares already held in trust. The RSUs will vest in ...
Simcere Pharmaceutical Delivers Double-Digit Growth on Innovative Drug Momentum
Aug 20, 2026
Simcere Pharmaceutical Group reported strong interim results for the six months ended June 30, 2026, driven by its innovative pharmaceutical business across neuroscience, oncology and autoimmune treatments. Revenue rose 27.8% year-on-year to RMB4,...
Simcere Launches RMB1 Billion Share Buyback to Signal Confidence in Outlook
Aug 20, 2026
Simcere Pharmaceutical Group Limited has announced that its board will activate a previously approved share repurchase mandate, allowing the company to buy back up to 10% of its issued shares through open-market transactions. The program, capped a...
Simcere Pharmaceutical Details Board and Committee Structure
Aug 20, 2026
Simcere Pharmaceutical Group Limited has detailed the composition of its board of directors, naming three executive directors, one non-executive director, and four independent non-executive directors. The company highlights the dual role of Chairm...
Simcere Reshapes Company Secretarial Team to Strengthen Governance
Aug 20, 2026
Simcere Pharmaceutical Group Limited announced changes to its company secretarial team, with executive director and chief financial officer Wan Yushan stepping down from his role as joint company secretary while remaining in his other positions. T...
Simcere Sets August 20 Board Meeting to Review Interim Results and Dividend Plan
Aug 10, 2026
Simcere Pharmaceutical Group Limited has scheduled a board meeting for August 20, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026, and to consider the publication of these results. The board will al...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.